Our Work
Latham Advises Theradaptive on Strategic Partnership with ATEC
January 14, 2026
Agreement established for breakthrough regenerative technology in spinal fusion.
Latham & Watkins has advised Theradaptive, Inc., a clinical-stage regenerative medicine company pioneering engineered protein therapeutics, on its strategic partnership with Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing spine surgery.
Under the terms of the agreement, ATEC gains exclusive US commercial rights to market and distribute Theradaptive's OsteoAdapt® osteoinductive bone graft for spinal fusion.
The Latham team was led by London counsel Oliver Mobasser.